Amryt\'s epidermolysis bullosa trial extended

Amryt's epidermolysis bullosa trial extended

05:34 EST 1 Mar 2019 | PharmaTimes

Amryt’s AP101 EASE Phase III trial has been extended to include infants aged 21 days to four years.

Original Article: Amryt's epidermolysis bullosa trial extended

More From BioPortfolio on "Amryt's epidermolysis bullosa trial extended"